| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -13,689 | -11,761 | -12,708 | -24,317 |
| Depreciation | 149 | 143 | 128 | 205 |
| Gain from sale of property, plant and equipment | NaN | -1 | 15 | NaN |
| Change in fair value of marketable securities, net of interest received | -64 | 181 | 23 | 155 |
| Change in liability for employees rights upon retirement | -102 | 351 | -94 | -277 |
| Other financial expenses (income) | -14 | 20 | 55 | 58 |
| Change in operating right of use asset and operating leasing liability | 18 | -74 | -103 | -377 |
| Share-based compensation expenses | 2,105 | 2,848 | 3,544 | 5,940 |
| Gain on amounts funded in respect of employee rights upon retirement, net | NaN | 299 | NaN | NaN |
| Loss (gains) on amounts funded in respect of employee rights upon retirement, net | -112 | NaN | 26 | 95 |
| Decrease in prepaid expenses | -96 | 351 | -2 | -113 |
| Increase in trade receivables | 213 | 207 | 369 | 20 |
| Decrease (increase) in other receivables | 7 | -75 | -21 | -186 |
| (increase) decrease in inventory | -360 | -211 | 553 | 484 |
| Increase in trade payables | 699 | -498 | 235 | 264 |
| Decrease in other payables | -1,990 | 850 | 989 | 642 |
| Net cash used in operating activities | -12,337 | -9,345 | -8,633 | -17,125 |
| Purchase of property, plant and equipment | 194 | 398 | 329 | 935 |
| Proceeds from sale of property, plant and equipment | NaN | 0 | 15 | NaN |
| Investments in marketable securities | NaN | 45,091 | 0 | 11,749 |
| Proceeds from matured marketable securities | 15,000 | 0 | 7,888 | 19,760 |
| Amounts funded in respect of employee rights upon retirement | 27 | 16 | 23 | 52 |
| Amounts withdrawn in respect of employee rights upon retirement | NaN | 370 | NaN | NaN |
| Net cash provided by investing activities | 14,779 | -45,135 | 7,551 | 7,024 |
| Proceeds from exercise of warrants, net of 1,000 issuance costs | NaN | 0 | 14,908 | 1,947 |
| Proceeds from issuance of shares and pre-funded warrants, net of 3,148 and 1 issuance costs, respectively | NaN | NaN | 38,018 | 696 |
| Proceeds from issuance of shares and pre-funded warrants, net of 3,148 and 81 issuance costs, respectively | NaN | 38,714 | NaN | NaN |
| Net cash provided by financing activities | NaN | 0 | 52,926 | 2,643 |
| Effect of exchange rate changes on cash and cash equivalents | -19 | 16 | 50 | 51 |
| Increase (decrease) in cash and cash equivalents | 2,423 | -54,464 | 51,894 | -7,407 |
| Balance of cash and cash equivalents at beginning of the period | 8,939 | 63,403 | 18,916 | NaN |
| Balance of cash and cash equivalents at end of the period | 11,362 | 8,939 | 63,403 | NaN |
InspireMD, Inc. (NSPR)
InspireMD, Inc. (NSPR)